NUTX Financials

Income Statement
MetricQ3 2026Q2 2026Q1 2026Q4 2025Q3 2025
Revenue
217.6M
+3.3%
210.8M
-2.6%
216.5M
+42.7%
151.7M
-43.4%
267.8M
Cost of Revenue
0
0
0
0
0
Gross Profit
217.6M
+3.3%
210.8M
-2.6%
216.5M
+42.7%
151.7M
-43.4%
267.8M
Operating Expenses
140.5M
+57.8%
89.0M
-34.2%
135.2M
+12.0%
120.8M
-12.1%
137.4M
R&D
0
0
0
0
0
SG&A
72.8M
+16.9%
62.3M
+20.1%
51.9M
+196.7%
-53663000
-184.7%
63.3M
Operating Income
77.1M
-36.7%
121.7M
+49.8%
81.3M
+162.8%
30.9M
-76.3%
130.4M
EBITDA
82.7M
-34.9%
127.0M
+46.4%
86.8M
+140.3%
36.1M
-73.3%
135.4M
Net Income
57.3M
-40.5%
96.3M
+53.5%
62.8M
+277.9%
16.6M
-82.8%
96.8M
EPS (Basic)
$5.87
-38.7%
$9.58
+43.0%
$6.70
+301.2%
$1.67
-79.8%
$8.27
EPS (Diluted)
$5.71
-39.1%
$9.38
+43.9%
$6.52
+307.5%
$1.60
-79.4%
$7.76
Shares (Diluted)
7.0M
+0.3%
7.0M
-2.2%
7.2M
-3.0%
7.4M
+3.1%
7.2M
Nutex Health (NUTX) — Financials